With $1M in VC Cash, Ligon Discovery Gets Set to Commercialize Small-Molecule Microarrays
December 01, 2009
With $1M in VC Cash, Ligon Discovery Gets Set to Commercialize Small-Molecule Microarrays
CEO Patrick Kleyn said this week that the Cambridge, Mass.-based startup is looking to partner with pharmaceutical and biotechnology companies that would like to use the firm's small-molecule microarrays, or SMMs, in their drug-discovery programs.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Ligon Discovery Sees Bayer-Schering Deal as Springboard to More Pharma Partnerships
October 5, 2010 / BioArray News - Ligon Discovery, Lycera Partner to Develop Drugs for Immune Disorders
February 16, 2010 / BioArray News - Agilent Restructures, Laying off 450; Q2 Revenues Flat
May 15, 2013 / GenomeWeb Daily News - TCGA Analysis Uncovers Four Molecular Subtypes for Endometrial Cancer
May 1, 2013 / GenomeWeb Daily News - Roche's Peptide Array, Sequence Capture Programs Unaffected by Planned Restructuring
April 30, 2013 / BioArray News